Medicine information bulletin, Volume 2, Issue 2, October 2025

dc.contributor.author	Ethiopian Food and Drug Authority
dc.date.accessioned	2026-02-24T10:30:02Z
dc.date.available	2026-02-24T10:30:02Z
dc.date.issued	2025
dc.identifier.uri	http://repository.iphce.org/xmlui/handle/123456789/5360
dc.description.abstract	LEN is given as a 927 mg subcutaneous injection every six months. Patients must be confirmed HIV-negative before the first and each subsequent dose. The injection is administered by a trained health professional under aseptic conditions. Because the drug persists in the body for a long time, missed or delayed doses may increase the risk of HIV infection and resistance, making timely administration essential.	en_US
dc.language.iso	en_US	en_US
dc.subject		en_US
dc.title	Medicine information bulletin, Volume 2, Issue 2, October 2025	en_US
dc.type	Bulletin	en_US